-
admin
Posts
Yalla Group Limited Announces Unaudited Second Quarter 2024 Financial Results
DUBAI, UAE, Aug. 13, 2024 /PRNewswire/ — Yalla Group Limited (“Yalla” or the “Company”) (NYSE: YALA), the largest Middle East and North Africa (MENA)-based online...
Yoshitsu Co., Ltd Establishes Franchise Network for Southeast Asia Expansion
TOKYO, Aug. 12, 2024 (GLOBE NEWSWIRE) — Yoshitsu Co., Ltd (“Yoshitsu” or the “Company”) (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health...
Collagen Peptide and Gelatin Market Size is Surpassing USD 10.51 Billion by 2033, Growing at Projected 5.93% CAGR
The collagen peptide and gelatin market size are projected to witness robust growth over the coming years, as a result of rising demand for protein-rich...
Burberry Group Digital Transformation Strategy 2024: Accelerators, Incubators and Innovation Programs
Dublin, Aug. 12, 2024 (GLOBE NEWSWIRE) — The “Enterprise Tech Ecosystem Series: Burberry Group Plc 2024” company profile has been added to ResearchAndMarkets.com’s offering. Burberry...
Global Nitrile Gloves Market Poised for Exceptional Growth, Projected CAGR of 24.9% through 2031: Hygiene-Centric Industries Fueling Demand, Technological Advancements Spearheading Market Growth
Dublin, Aug. 12, 2024 (GLOBE NEWSWIRE) — The “Nitrile Gloves Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 – By Product,...
Probiotics Market Report 2024-2030: Integration of Probiotics into Beauty and Skin Care Products Throws the Spotlight On Cosmeceuticals
Dublin, Aug. 12, 2024 (GLOBE NEWSWIRE) — The “Probiotics – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering. The global market for Probiotics...
Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Presented cohort one (low dose) data from both trials of TSHA-102 at 2024 IRSF Rett Syndrome Scientific Meeting that demonstrated durable improvements across consistent clinical...
MBX Biosciences Doses First Patient in Phase 2 Avail™ Trial of MBX 2109 for the Treatment of Hypoparathyroidism
Topline results expected in Q3 2025 CARMEL, Ind., Aug. 12, 2024 (GLOBE NEWSWIRE) — MBX Biosciences, Inc., a clinical stage biopharmaceutical company focused on the...
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
First-line monotherapy data for once daily firmonertinib selected as an oral presentation in the presidential session First prospectively designed randomized clinical data for a small-molecule...
LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on...